QIAGEN QGEN recently unveiled its latest offering, the QuantiFERON-EBV RUO (Research Use Only) assay. This addition to the company’s existing QuantiFERON portfolio of tests marks a significant step ...
QIAGEN leverages QuantiFERON®-TB technology to advance global efforts against TB TB IGRA testing now accessible in high burden, low resource and decentralized settings Study data also showcased at the ...
The MHRA has approved Siiltibcy, a new skin test that uses recombinant proteins to more accurately detect tuberculosis in ...
Germantown, Md. & HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the U.S. launch of an automated ...
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
HILDEN, Germany & GERMANTOWN, Md. & SHANGHAI--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON tuberculosis (TB) testing solution has ...
QIAGEN N.V. QGEN recently announced the receipt of Japan’s Ministry of Health Labor and Welfare approval for QuantiFERON-TB Gold Plus (QFT-Plus) as an in vitro diagnostic to detect tuberculosis (TB) ...
Jan. 11, 2005 — The U.S. Food and Drug Administration (FDA) has approved a test to identify individual patient variations in drug metabolism; an implant system that simplifies the arthroscopic ...
To describe the use of the second-generation QuantiFERON-TB Gold (QFT-G) test in a series of patients in an ophthalmic practice. The charts of all patients who had QFT-G tests ordered by Mayo Clinic ...
Enabling highly automated screening solution for latent tuberculosis in all throughput segments Embedding QuantiFERON assays in the broad assay menu of DiaSorin’s LIAISON analyzers also gives current ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback